Joan T Merrill Selected Research

AMG623 peptibody

1/2018	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
8/2015	Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joan T Merrill Research Topics

Disease

89	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2022 - 07/2002
21	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 10/2020 - 03/2003
18	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 12/2004
10	Lupus Nephritis 11/2022 - 11/2005
10	Thrombosis (Thrombus) 01/2021 - 03/2003
8	Infections 01/2019 - 10/2012
7	Inflammation (Inflammations) 01/2021 - 01/2010
6	Atherosclerosis 03/2010 - 09/2002
5	Rheumatoid Arthritis 01/2018 - 04/2006
4	Neoplasms (Cancer) 12/2021 - 06/2003
4	Nephritis 06/2017 - 04/2009
3	Arthritis (Polyarthritis) 01/2022 - 01/2018
3	Hypertension (High Blood Pressure) 01/2019 - 09/2015
3	Proteinuria 01/2018 - 02/2014
3	Exanthema (Rash) 01/2018 - 10/2011
3	Herpes Zoster 01/2017 - 02/2014
3	Human Influenza (Influenza) 01/2017 - 08/2011
3	Venous Thrombosis (Deep-Vein Thrombosis) 12/2005 - 01/2004
2	Headache (Headaches) 12/2021 - 11/2013
2	COVID-19 01/2021 - 10/2020
2	Pre-Eclampsia (Preeclampsia) 01/2019 - 10/2003
2	Stroke (Strokes) 10/2018 - 06/2006
2	Chronic Kidney Failure (Chronic Renal Failure) 12/2017 - 05/2009
2	Neurologic Manifestations (Neurological Manifestations) 01/2016 - 04/2006
2	Genetic Predisposition to Disease (Genetic Predisposition) 12/2015 - 01/2013
2	malar rash 01/2015 - 10/2011
2	Thrombotic Thrombocytopenic Purpura 01/2015 - 04/2008
2	Alzheimer Disease (Alzheimer's Disease) 11/2005 - 06/2003
1	Neutropenia 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Skin Neoplasms (Skin Cancer) 12/2021
1	Breast Neoplasms (Breast Cancer) 12/2021
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Disseminated Intravascular Coagulation 10/2020
1	Hemorrhage 10/2020
1	Thrombotic Microangiopathies 10/2020
1	Communicable Diseases (Infectious Diseases) 01/2020
1	Migraine with Aura (Familial Hemiplegic Migraine) 01/2019

Drug/Important Bio-Agent (IBA)

19	AutoantibodiesIBA 01/2019 - 06/2003
12	AntibodiesIBA 01/2021 - 10/2003
11	InterferonsIBA 01/2022 - 11/2011
10	Monoclonal AntibodiesIBA 11/2022 - 12/2002
10	belimumabIBA 11/2022 - 01/2008
9	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2008
9	Antiphospholipid AntibodiesIBA 01/2018 - 01/2004
8	Biological ProductsIBA 04/2022 - 01/2008
8	Antinuclear AntibodiesIBA 01/2022 - 04/2006
7	B-Cell Activating FactorIBA 11/2022 - 01/2008
7	Estrogens (Estrogen)FDA Link 01/2018 - 06/2005
6	Immunoglobulin G (IgG)IBA 01/2021 - 03/2003
6	Interferon Type IIBA 01/2018 - 01/2010
5	anifrolumabIBA 01/2022 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2003
5	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 10/2018 - 06/2005
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2016 - 10/2003
4	GlucocorticoidsIBA 01/2022 - 02/2014
4	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 07/2002
4	Complement System Proteins (Complement)IBA 10/2020 - 01/2013
4	SteroidsIBA 01/2018 - 07/2002
4	DNA (Deoxyribonucleic Acid)IBA 06/2017 - 04/2009
4	Dehydroepiandrosterone (DHEA)IBA 11/2005 - 07/2002
3	TACI receptor-IgG Fc fragment fusion proteinIBA 11/2021 - 08/2008
3	LigandsIBA 01/2018 - 06/2003
3	CytokinesIBA 12/2014 - 01/2013
3	interleukin-21 (interleukin 21)IBA 10/2011 - 08/2009
3	CholesterolIBA 03/2010 - 09/2002
3	beta 2-Glycoprotein I (Apolipoprotein H)IBA 04/2008 - 06/2003
3	Anticardiolipin AntibodiesIBA 12/2005 - 03/2003
2	iberdomideIBA 04/2022 - 01/2022
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 12/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 11/2005
2	Antimalarials (Antimalarial Agents)IBA 12/2021 - 11/2013
2	AMG623 peptibodyIBA 01/2018 - 08/2015
2	Antirheumatic Agents (DMARD)IBA 01/2018 - 11/2014
2	tocilizumab (atlizumab)FDA Link 01/2018 - 11/2014
2	CreatinineIBA 06/2017 - 02/2014
2	sifalimumabIBA 11/2016 - 11/2011
2	Prostaglandins AIBA 01/2016 - 08/2015
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2013 - 04/2008
2	Endothelial Protein C ReceptorIBA 03/2012 - 05/2009
2	Interleukin-2 (IL2)IBA 09/2011 - 06/2011
2	Prednisone (Sone)FDA LinkGeneric 08/2011 - 07/2002
2	Protein SIBA 01/2010 - 10/2003
2	Rituximab (Mabthera)FDA Link 01/2010 - 10/2003
2	Pharmaceutical PreparationsIBA 06/2009 - 12/2004
2	CD11b AntigenIBA 03/2009 - 02/2008
2	LipidsIBA 06/2003 - 09/2002
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 12/2021
1	BNT162 VaccineIBA 01/2021
1	Platelet Factor 4IBA 01/2021
1	VaccinesIBA 01/2021
1	Thromboplastin (Tissue Factor)IBA 01/2021
1	FibrinIBA 01/2021
1	Dacarbazine (DIC)FDA LinkGeneric 10/2020
1	Fibrinogen (Factor I)FDA Link 10/2020
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2020
1	Contraceptive Agents (Contraceptives)IBA 01/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019

Therapy/Procedure

15	Therapeutics 11/2022 - 09/2004